公开(公告)号：WO2016120632A1

公开(公告)日：2016-08-04

申请号：PCT/GB2016/050199

申请日：2016-01-29

Applicant: THE UNIVERSITY OF BIRMINGHAM

Inventor： AFFORD, Simon ,  WILHELM, Annika

IPC: G01N33/574 ,  G01N33/68

CPC classification number: G01N33/57438 ,  G01N33/6893 ,  G01N2800/065 ,  G01N2800/08 ,  G01N2800/085

Abstract: The invention provides a method of diagnosis or prognosis of a chronic liver disease or inflammatory bowel disease (IBD) in a subject comprising providing a sample from the subject and measuring the amount of TWEAK (tumour necrosis factor-like weak inducer of apoptosis) in the sample, wherein if the amount of TWEAK is below a predetermined level, then there is an increased risk that the subject has a chronic liver disease or has a poor prognosis of the chronic liver disease, or if the amount is above a predetermined level then there is an increased risk that the subject has IBD. The invention also provides a method of determining the effect of treatment on a chronic liver disease comprising providing measuring the amount of TWEAK in a first sample from a subject, provided before the treatment and comparing it to an amount of TWEAK in a second sample from a subject provided after treatment, wherein an increase in TWEAK between the first and second samples indicates that the chronic liver disease is being treated. Assay kits for use in the invention are also provided.

Abstract translation: 本发明提供了一种在受试者中诊断或预后的慢性肝病或炎性肠病（IBD）的方法，包括从受试者提供样品并测量TWEAK（肿瘤坏死因子样弱凋亡诱导剂）的量 样本，其中如果TWEAK的量低于预定水平，则受试者具有慢性肝病或慢性肝病的预后不良的风险增加，或者如果该量高于预定水平，那么那里 受试者患IBD的风险增加。 本发明还提供了一种确定治疗对慢性肝病的影响的方法，包括提供在治疗前提供的测量来自受试者的第一样品中TWEAK的量，并将其与第二样品中TWEAK的量 治疗后提供受试者，其中第一和第二样品之间TWEAK的增加表明正在治疗慢性肝病。 还提供了用于本发明的测定试剂盒。